An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.

Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.

Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?

Abstract titles reveal some of ASCO’s key datasets.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

The company's comparison of its ADCs to Enhertu seems farfetched.